US20100267775A1 - Oxadiazolidinedione compound - Google Patents

Oxadiazolidinedione compound Download PDF

Info

Publication number
US20100267775A1
US20100267775A1 US12/739,501 US73950108A US2010267775A1 US 20100267775 A1 US20100267775 A1 US 20100267775A1 US 73950108 A US73950108 A US 73950108A US 2010267775 A1 US2010267775 A1 US 2010267775A1
Authority
US
United States
Prior art keywords
oxadiazolidine
dione
benzyl
methyl
oxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US12/739,501
Other languages
English (en)
Inventor
Kenji Negoro
Fumiyoshi Iwasaki
Kei Ohnuki
Toshio Kurosaki
Kazuyuki Tsuchiya
Kazuyuki Kuramoto
Shigeru Yoshida
Takatoshi Soga
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Astellas Pharma Inc
Original Assignee
Astellas Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astellas Pharma Inc filed Critical Astellas Pharma Inc
Assigned to ASTELLAS PHARMA INC. reassignment ASTELLAS PHARMA INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: IWASAKI, FUMIYOSHI, KURAMOTO, KAZUYUKI, KUROSAKI, TOSHIO, NEGORO, KENJI, OHNUKI, KEI, SOGA, TAKATOSHI, TSUCHIYA, KAZUYUKI, YOSHIDA, SHIGERU
Publication of US20100267775A1 publication Critical patent/US20100267775A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
    • C07D271/07—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Definitions

  • the present invention relates to an oxadiazolidinedione compound useful as a pharmaceutical agent, particularly as an insulin secretagogue or an agent for preventing and/or treating diabetes mellitus.
  • Diabetes mellitus is a disease whose cardinal sign is chronic hyperglycemia, and it occurs as a result of absolute or relative deficiency of insulin action. Diabetes mellitus is roughly classified into two types according to its diagnostic in clinical practice, which are insulin-dependent diabetes mellitus (type 1 diabetes) and non-insulin-dependent diabetes mellitus (type 2 diabetes). In the non-insulin-dependent diabetes mellitus, decrease in insulin secretion from ⁇ -cells of the pancreas is one of cardinal pathogenesis, and in particular, postprandial hyperglycemia which is caused by deficient secretion of insulin is recognized in the early stages.
  • sulfonylurea (SU) drugs are the mainstream as an insulin secretagogue, but it is known that the drug is likely to cause hypoglycemia and its chronic administration leads to secondary failure due to pancreatic exhaustion. Furthermore, the SU drug has a beneficial effect on glycemic control between meals, but it is difficult to suppress postprandial hyperglycemia.
  • GPR40 is a G protein-coupled receptor which is highly expressed in ⁇ cells of the pancreas and identified as a fatty acid receptor, and associated with the insulin secretagogue action of fatty acid (Non-Patent Document 1).
  • GPR40 receptor agonist is expected to correct postprandial hyperglycemia on the basis of insulin secretagogue action, and thus it is useful as an agent for preventing and/or treating insulin-dependent diabetes mellitus (type 1 diabetes), non-insulin-dependent diabetes mellitus (type 2 diabetes) and borderline thereof (impaired glucose tolerance/fasting blood glucose).
  • Patent Document 1 it is reported that a compound of the formula (A) including a wide range of compounds has GPR40 receptor regulatory action, and is useful as an insulin secretagogue or an agent for preventing and/or treating diabetes mellitus.
  • a compound of the formula (A) including a wide range of compounds has GPR40 receptor regulatory action, and is useful as an insulin secretagogue or an agent for preventing and/or treating diabetes mellitus.
  • ring P represents an aromatic ring which may have substituents
  • ring Q represents an aromatic ring which may have substituents other than the following:
  • X and Y each represents a spacer
  • Patent Document 2 it is reported that a compound of the formula (B) has GPR40 receptor regulatory action, and is useful as an insulin secretagogue or an agent for preventing and/or treating diabetes mellitus.
  • Patent Document 3 it is reported that a compound of the formula (C) has GPR40 receptor regulatory action, and is useful as an insulin secretagogue or an agent for preventing and/or treating diabetes mellitus.
  • Patent Document 4 it is reported that an oxadiazolidinedione compound of the formula (D) has plasminogen-activator inhibitor (PAI)-1 inhibitory action, and is useful for treating thrombus, atrial fibrillation, myocardial ischemia, diabetes mellitus or the like.
  • PAI plasminogen-activator inhibitor
  • Patent Document 5 it is reported that a compound of the formula (E) having two oxadiazolidinedione structures has insulin sensitivity potentiating action, and is useful for treating diabetes mellitus.
  • Patent Document 6 it is reported that an oxadiazolidinedione compound of the formula (F) has hypoglycemic action and hypolipidemic action in blood, and is useful for treating diabetes mellitus.
  • Patent Document 7 it is reported that an oxadiazolidinedione compound of the formula (G) has hypoglycemic action, and is useful for treating diabetes mellitus.
  • Patent Document 8 it is reported that a compound of the formula (H) has hypoglycemic action, and is useful for treating diabetes mellitus.
  • Patent Document 9 it is reported that an oxadiazolidinedione compound of the formula (J) has hypoglycemic action, and is useful for treating diabetes mellitus.
  • Patent Document 10 it is reported that a compound of the formula (K) is useful for hyperlipidemia, hyperglycemia, obesity or the like.
  • Non-Patent Document 2 it is reported that an oxadiazolidinedione compound of the formula (L) has hypoglycemic action, and is useful for treating diabetes mellitus.
  • Patent Document 11 it is reported that a compound of the formula (M) has GPR40 receptor regulatory action, and is useful as an insulin secretagogue or an agent for preventing and/or treating diabetes mellitus.
  • Patent Document 12 which was published after the priority date of the present application, it is reported that a compound of the formula (N) has GPR40 receptor regulatory action, and is useful as an insulin secretagogue or an agent for preventing and/or treating diabetes mellitus.
  • the present inventors have examined a compound having GPR40 receptor agonistic action, and as a result, they have found that an oxadiazolidinedione compound having a substituent such as a benzyl group etc. linked with a substituent such as a phenyl group etc. through a linker at the 2-position of an oxadiazolidinedione ring exhibits excellent GPR40 receptor agonistic action. Furthermore, they found that these oxadiazolidinedione compounds have excellent insulin secretagogue action and strongly suppress the rise in blood glucose after a glucose tolerance test. Thus they have completed the invention.
  • the present invention relates to a compound of the formula (I) or a pharmaceutically acceptable salt thereof, as well as a pharmaceutical composition containing the compound of the formula (I) or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable excipient.
  • L 1 and L 3 are the same with or different from each other and each represents CH or N;
  • L 2 represents O or NH
  • R 1 represents —H or C 1-6 alkyl
  • R 2 represents a group of the formula (II) or (III):
  • L 4 represents CH or N
  • a and B are the same with or different from each other and each represents —O—(C 1-6 alkyl substituted with one or more group(s) selected from G 1 group), amino which may be substituted with one or more group(s) selected from G 2 group, —H or —R 3 (provided that at least one of A and B represents a group other than —H and —R 3 );
  • R 3 is the same with or different from each other and represents C 1-6 alkyl which may be substituted with one or more group (s) selected from the group consisting of —OH and halogen, halogen or —O—(C 1-6 alkyl);
  • R 4 represents C 1-6 alkyl which is substituted with one or more group(s) selected from G 1 group;
  • n 1 or 2;
  • G 1 group represents the group consisting of —NHCO 2 R Z , —NH 2 , —NHCOR Z , —NHCO-(cycloalkyl), —NHCO-(aryl), —NHSO 2 R Z , 1,3-dioxolan-4-yl which may be substituted with 1 to 5 C 1-6 alkyl, —OH, —OCOR Z , —OR Z , —CO 2 R Z , —CO 2 H, —CONHR Z and —CON(R Z ) 2 ;
  • G 2 group represents the group consisting of —CO 2 R Z and —R Z ;
  • R Z is the same with or different from each other and represents C 1-6 alkyl which may be substituted with one or more group(s) selected from the group consisting of —OH and —OCO—(C 1-6 alkyl). The same shall apply hereinafter.
  • the present invention relates to a GPR40 receptor agonist or an insulin secretagogue which comprises a compound of the formula (I) or a pharmaceutically acceptable salt thereof.
  • the present invention relates to a pharmaceutical composition for preventing and/or treating diabetes mellitus which comprises a compound of the formula (I) or a pharmaceutically acceptable salt thereof, namely, an agent for preventing and/or treating diabetes mellitus which comprises a compound of the formula (I) or a pharmaceutically acceptable salt thereof.
  • the present invention relates to use of the compound of the formula (I) or a pharmaceutically acceptable salt thereof for producing an insulin secretagogue or an agent for preventing and/or treating diabetes mellitus, and a method for promotion of insulin secretion or a method for preventing and/or treating diabetes mellitus which includes administering an effective dose of the compound of the formula (I) or a salt thereof to patients.
  • composition which comprises the compound of the formula (I) or a pharmaceutically acceptable salt thereof, and a pharmaceutical acceptable excipient;
  • an insulin secretagogue which comprises the compound of the formula (I) or a pharmaceutical acceptable salt thereof;
  • composition for preventing and/or treating diabetes mellitus which comprises the compound of the formula (I) or a pharmaceutically acceptable salt thereof;
  • (6) a method for promotion of insulin secretion or a method for preventing and/or treating diabetes mellitus which includes administering an effective dose of the compound of the formula (I) or a salt thereof to patients.
  • the compound of the formula (I) or a pharmaceutically acceptable salt thereof has GPR40 receptor agonistic action, and can be used as insulin secretagogues and an agent for preventing and/or treating diseases associated with GPR40 such as diabetes mellitus (insulin-dependent diabetes mellitus (type 1 diabetes), non-insulin-dependent diabetes mellitus (type 2 diabetes) and borderline thereof (impaired glucose tolerance/fasting blood glucose), obesity and the like.
  • GPR40 receptor agonistic action can be used as insulin secretagogues and an agent for preventing and/or treating diseases associated with GPR40 such as diabetes mellitus (insulin-dependent diabetes mellitus (type 1 diabetes), non-insulin-dependent diabetes mellitus (type 2 diabetes) and borderline thereof (impaired glucose tolerance/fasting blood glucose), obesity and the like.
  • the present invention provides the following.
  • L 1 and L 3 are the same with or different from each other and each represents CH or N;
  • L 2 represents O or NH
  • R 1 represents —H or C 1-6 alkyl
  • R 2 represents a group of the formula (II) or (III):
  • L 4 represents CH or N
  • a and B are the same with or different from each other and represent —O—(C 1-6 alkyl substituted with one or more group(s) selected from G 1 group), amino which may be substituted with one or more group(s) selected from G 2 group, —H or —R 3 (provided that at least one of A and B represents a group other than —H and —R 3 );
  • R 3 is the same with or different from each other and represents C 1-6 alkyl which may be substituted with one or more group (s) selected from the group consisting of —OH and halogen, halogen or —O—(C 1-6 alkyl);
  • R 4 represents C 1-6 alkyl which is substituted with one or more group(s) selected from G 1 group;
  • n 1 or 2;
  • G 1 group represents the group consisting of —NHCO 2 R Z , —NH 2 , —NHCOR Z , —NHCO-(cycloalkyl), —NHCO-(aryl), —NHSO 2 R Z , 1,3-dioxolan-4-yl which may be substituted with 1 to 5 C 1-6 alkyl, —OH, —OCOR Z , —OR Z , —CO 2 R Z , —CO 2 H, —CONHR Z and CON(R Z ) 2 ;
  • G 2 group represents the group consisting of —CO 2 R Z and —R Z ;
  • R Z is the same with or different from each other and represents C 1-6 alkyl which may be substituted with one or more group(s) selected from the group consisting of —OH and —OCO—(C 1-6 alkyl))
  • a pharmaceutical composition which comprises the compound as described in [1] or a pharmaceutically acceptable salt thereof, and a pharmaceutical acceptable excipient.
  • a GPR40 agonist which comprises the compound as described in [1] or a pharmaceutically acceptable salt thereof.
  • a pharmaceutical composition for prevention and/or treating diabetes mellitus which comprises the compound as described in [1] or a pharmaceutically acceptable salt thereof.
  • a method of promoting insulin secretion or a method of preventing and/or treating diabetes mellitus which comprises administering an effective amount of the compound as described in [1] or a salt thereof to a patient.
  • C 1-6 alkyl is linear or branched alkyl having 1 to 6 carbon atom(s), for example, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl, n-hexyl or the like.
  • Halogen means F, Cl, Br and I.
  • Cycloalkyl is a “C 3-10 saturated hydrocarbon cyclic group, for example, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, adamantly group or the like. Another aspect is a cycloproyl, cyclobutyl, cyclopentyl or cyclohexyl group.
  • Aryl is a “C 6-14 aromatic hydrocarbon cyclic group, for example, a phenyl, naphthyl, tetrahydronaphthyl group or the like. Another aspect is a phenyl group.
  • “may be substituted” means being unsubstituted or having 1 to 5 substituent(s), and another aspect means being unsubstituted or having 1 to 2 substituent(s). “Substituted” means having 1 to 5 substituent(s), and another aspect means having 1 to 2 substituent(s). In the case of having a plurality of substituents, they may be the same with or different from each other.
  • R 2 is a group of the formula (II), either one of A and B is —O—(C 1-6 alkyl which is substituted with one or more group(s) selected from G 1 group), the other of A or B is —H or —R 3 .
  • R 2 is a group of the formula (II), either one of A and B is —O—(C 1-6 alkyl which is substituted with one or more group(s) selected from the group consisting of —NHCOR Z , —NHCO-(cycloalkyl), —OH and —OR Z ), R Z is C 1-6 alkyl which may be substituted with one or more —OH, and the other of A or B is —H, methyl or halogen.
  • R 2 is a group of the formula (II), either one of A and B is —O—(C 1-6 alkyl which is substituted with one or more group(s) selected from the group consisting of —NHCOR Z , —NHCO-(cycloalkyl), —OH and —OR Z ), R Z is C 1-6 alkyl which may be substituted with one or more —OH, the other of A or B is —H, and n is 2.
  • R 2 is a group of the formula (II), either one of A and B is —O—(C 1-6 alkyl which is substituted with one or more group(s) selected from the group consisting of —NHCOR Z , —NHCO-(cycloalkyl), —OH and —OR Z ), R Z is C 1-6 alkyl which may be substituted with one or more —OH, the other of A or B is methyl or halogen, and n is 1.
  • A is —O—(C 1-6 alkyl which is substituted with one or more group(s) selected from the group consisting of —NHCOR Z , —NHCO-(cycloalkyl), —OH and —OR Z ), R Z is C 1-6 alkyl which may be substituted with one or more —OH, and B is —H, methyl or halogen.
  • R 2 is a group of the formula (II)
  • A is —O—(C 1-6 alkyl which is substituted with one or more group(s) selected from the group consisting of —NHCOR Z , —NHCO-(cycloalkyl), —OH and —OR Z ),
  • R Z is C 1-6 alkyl which may be substituted with one or more —OH
  • B is —H
  • n is 2.
  • R 2 is a group of the formula (II)
  • A is —O—(C 1-6 alkyl which is substituted with one or more group(s) selected from the group consisting of —NHCOR Z , —NHCO-(cycloalkyl), —OH and —OR Z )
  • R Z is C 1-6 alkyl which may be substituted with one or more —OH
  • B is methyl or halogen
  • n is 1.
  • a compound in which R 2 is a group of the formula (II)
  • A is —O—(C 1-6 alkyl substituted with one or more —OH)
  • B is —H, methyl or halogen.
  • R 2 is a group of the formula (II)
  • R 3 is the same with or different from each other and is methyl which may be substituted with one or more halogen, halogen or —O-methyl.
  • 4-2) As another aspect, a compound in which R 2 is a group of the formula (II) and R 3 is methyl.
  • Compounds included in the present invention may include the following:
  • the following compound may include:
  • compound of the formula (I) in the compound of the formula (I) and a pharmaceutically acceptable salt thereof (hereinafter, may be referred to as “compound of the formula (I)”), other tautomers or geometric isomers may exist depending on the kind of substituents.
  • compound of the formula (I) a pharmaceutically acceptable salt thereof
  • other tautomers or geometric isomers may exist depending on the kind of substituents.
  • the present invention includes these isomers, and also includes separated isomers or mixtures thereof.
  • the compound of the formula (I) may have asymmetric carbon atoms or axial asymmetry, and optical isomers such (R)-form and (S)-form may exist on the basis of this.
  • the present invention includes all of the mixtures and isolated forms of these optical isomers.
  • the present invention also includes a pharmaceutically acceptable prodrug of the compound of the formula (I).
  • the pharmaceutically acceptable prodrug is a compound having a group which can convert into an amino group, a hydroxyl group, a carboxyl group or the like of the compound of the formula (I) by solvolysis or under physiological conditions.
  • a group forming a prodrug may include a group described in, for example, “PROGRESS IN MEDICINE”, 5, 2157-2161 (1985) and “Iyakuhin no Kaihatsu”, (Hirokawa shoten, 1990) Vol. 7 Molecular Design 163-198.
  • the compound of the formula (I) may form a salt with an acid addition salt or a base depending on the kind of substituents, and such salt is included in the present invention as long as the salt is a pharmaceutically acceptable salt.
  • Specific examples thereof may include acid addition salts with an inorganic acid such as hydrochloric acid, hydrobromic acid, hydroiodic acid, sulfuric acid, nitric acid and phosphoric acid, etc., or an organic acid such as formic acid, acetic acid, propionic acid, oxalic acid, malonic acid, succinic acid, fumaric acid, maleic acid, lactic acid, malic acid, mandelic acid, tartaric acid, dibenzoyltartaric acid, ditoluoyltartaric acid, citric acid, methanesulfonic acid, ethanesulfonic acid, benzenesulfonic acid, p-toluenesulfonic acid, aspartic acid and glutamic acid, etc.; salts
  • the present invention also includes substances of various hydrates, solvates and crystalline polymorphs of the compound of the formula (I) and a pharmaceutically acceptable salt. Moreover, the invention also includes various radiolabeled or non-radiolabeled compounds.
  • the compound of the formula (I) and a pharmaceutically acceptable salt thereof can be produced by applying various known synthetic methods by making use of the feature based on its basic skeleton or the kind of substituents. At the time, it may be effective in the producing technique that the relevant functional group is replaced by a proper protecting group (group capable of easily converting into the relevant functional group) at the stage of a raw material to an intermediate, depending on the kind of substituents.
  • a proper protecting group group capable of easily converting into the relevant functional group
  • Such protecting group may include, for example, protecting groups described in “Protective Groups in Organic Synthesis (the 3 rd edition, 1999)” written by Greene and Wuts and the like, and may be optionally selected and used according to these reaction conditions. In the method like this, a desired compound can be obtained by removing the protecting group after introducing the protecting group to react.
  • the prodrug of the formula (I) can be produced by introducing the specific group at the stage of a raw material to an intermediate, or further reacting with the use of the obtained compound of the formula (I), the same as the above-mentioned protecting group.
  • the reaction can be carried out by applying the method known to those skilled in the art such as normal esterification, amidation, dehydration or the like.
  • the production method is a method for producing a compound (I) of the invention by a ring construction reaction using a compound (1) and a compound (2).
  • a compound (1) and a compound (2) for the leaving group of Lv, halogen such as chloro, bromo, etc.; and an alkoxy group such as methoxy, ethoxy, etc. are preferred.
  • the reaction can be carried out by using the compound (1) and the compound (2), in which the compound have equal amount or one compound has excessive amount, in a solvent of ethers such as diethyl ether, tetrahydrofuran (THF), dioxane, dimethoxyethane (DME), etc.; halogenated hydrocarbons such as dichloromethane, 1,2-dichloroethane, chloroform, etc.; aromatic hydrocarbons such as benzene, toluene, xylene, etc.; or the like, under cooling, room temperature or heating.
  • ethers such as diethyl ether, tetrahydrofuran (THF), dioxane, dimethoxyethane (DME), etc.
  • halogenated hydrocarbons such as dichloromethane, 1,2-dichloroethane, chloroform, etc.
  • aromatic hydrocarbons such as benzene, toluene, xylene, etc.; or
  • the hydroxyl group may be carbamoylated.
  • the carbamoyl group can be removed by the method in which those skilled in the art usually use for decarbamoylation. More specifically, the method can be carried out, for example, using a base such as sodium methoxide, sodium ethoxide, sodium hydroxide, etc. in a solvent of an alcohol such as methanol, ethanol, etc., water, or the like under cooling, room temperature or heating.
  • Lv 1 and Lv 2 represents halogen or a trifluoromethanesulfonyloxy group, and the other represents —B(OH) 2 , —B(OR 0 ) 2 and —Sn(C 1-6 alkyl) 3 ;
  • R 0 means C 1-6 alkyl and two R 0 s may form C 2-6 alkylene. The same shall apply hereinafter.
  • the production method is a method for producing a compound (I) of the invention by a coupling reaction between a compound (3) and a compound (4).
  • the reaction can be carried out by using the compound (3) and the compound (4), in which the compound have equal amount or one compound has excessive amount, using a palladium complex such as tetrakistriphenylphosphine palladium, palladium acetate or the like as a catalyst, in a solvent such as ethers, alcohols, halogenated hydrocarbons, aromatic hydrocarbons, water, etc. or mixed solvent thereof, under cooling, room temperature or heating. It may be favorable in smooth progress of the reaction that the reaction is carried out in the presence of a base such as sodium carbonate, cesium carbonate, sodium tert-butoxide or the like, or a lithium salt such as lithium chloride, lithium bromide or the like.
  • a base such as sodium carbonate, cesium carbonate, sodium tert-butoxide or the like
  • a lithium salt such as lithium chloride, lithium bromide or the like.
  • the production method is a method for producing a compound (I-a) of the invention by reductively aminating a compound (5) using a compound (6).
  • the reaction is carried out by stirring in the presence of a reducing agent in a solvent inert to the reaction under heating to reflux from ⁇ 45° C., preferably at 0° C. to room temperature for normally 0.1 hours to 5 days, using the compound (5) and the compound (6), in which the compound have equal amount or one compound has excessive amount.
  • the solvent may include, for example, alcohols, ethers and mixtures thereof.
  • the reducing agent may include sodium cyanoborohydride, sodium triacetoxyborohydride, sodium borohydride and the like.
  • the reaction may be preferred to carry out in the presence of a dehydrating agent such as molecular sieves etc., or an acid such as acetic acids, hydrochloric acids, titanium (IV) isopropoxide complexes, etc.
  • a dehydrating agent such as molecular sieves etc.
  • an acid such as acetic acids, hydrochloric acids, titanium (IV) isopropoxide complexes, etc.
  • a reduction reaction may be separately carried out after obtaining the imine compound.
  • some compounds of the formula (I) also can be produced by optionally combining adoptable processes such as known amidation, oxidation, hydrolysis and the like for those skilled in the art from compounds of the invention as obtained above. Specifically, the following reaction can be applied.
  • An amide compound can be obtained by a reaction of a carboxylic compound with an amine compound.
  • the condensing agent may include 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide (EDCI) or a salt thereof, dicyclohexylcarbodiimide, 1,1′-carbonyldiimidazole, diphenylphosphoryl azide and phosphorous oxychloride, but it is not limited to these. It may be favorable to use additives (e.g., 1-hydroxybenzotriazole) in smooth progress of the reaction.
  • EDCI 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide
  • additives e.g., 1-hydroxybenzotriazole
  • reaction is carried out in the presence of an organic base such as triethylamine, N,N-diisopropylethylamine and N-methylmorpholine, etc., or an inorganic base such as potassium carbonate, sodium carbonate, potassium hydroxide, etc.
  • organic base such as triethylamine, N,N-diisopropylethylamine and N-methylmorpholine, etc.
  • inorganic base such as potassium carbonate, sodium carbonate, potassium hydroxide, etc.
  • the method to react with an amine compound after converting a carboxylic compound into a reactive derivative can be used.
  • the reactive derivative of the carboxylic acid may include an acid halide obtained by a reaction with a halogenating agent such as phosphorous oxychloride, thionyl chloride or the like; mixed acid anhydride obtained by a reaction with isobutyl chloroformate or the like; active ester obtained by condensation with 1-hydroxybenzotriazole or the like; and the like.
  • the reaction of these reactive derivatives with the amine compound can be carried out in a solvent inert to the reaction of halogenated hydrocarbons, aromatic hydrocarbons, ethers or the like under cooling to heating, preferably at ⁇ 20 to 60° C.
  • a sulfoxide compound or a sulfone compound can be produced by oxidizing the S atom of a sulfide compound with various oxidizing agents.
  • the reaction can be carried out, for example, by using m-chloroperbenzoic acid, peracetic acid, a hydrogen peroxide solution, Dess-Martin reagent (1,1,1-triacetoxy-1,1-dihydro-1,2-benziodoxol-3(1H)one) or the like as an oxidizing agent with an equal amount to excessive amount in a solvent such as halogenated hydrocarbons, acetic acid, water etc., under cooling, room temperature or heating.
  • a solvent such as halogenated hydrocarbons, acetic acid, water etc.
  • a compound having a carboxyl group can be produced by hydrolysis of a compound having an ester group.
  • the reaction can be carried out in a solvent inert to the reaction such as aromatic hydrocarbons, ethers, halogenated hydrocarbons, alcohols, DMF, DMA, N-methyl-2-pyrrolidinone (NMP), DMSO, pyridine, water, etc., in the presence of an acid such as mineral acid such as sulfuric acid, hydrochloric acid, hydrobromic acid, etc.; an organic acid such as formic acid, acetic acid, etc., or the like; or in the presence of a base such as lithium hydroxide, sodium hydroxide, potassium hydroxide, potassium carbonate, sodium carbonate, cesium carbonate, ammonia, etc., under cooling or heating.
  • a solvent inert such as aromatic hydrocarbons, ethers, halogenated hydrocarbons, alcohols, DMF, DMA, N-methyl-2-pyrrolidinone (NMP), DMSO,
  • a raw material to be used for producing the invention can be manufactured by applying, for example, the following method, a method described in production methods as follows, known methods or obvious methods for those skilled in the art, or modified methods thereof.
  • Lv 3 represents —OH, or a leaving group such as halogen, methanesulfonyloxy, p-toluenesulfonyloxy or the like. The same shall apply hereinafter.
  • the production method is a method for obtaining a compound (9) by O-alkylating a compound (8) with a compound (7).
  • the method can be carried out by Mitsunobu reaction in which those skilled in the art normally use. More specifically, the method can be carried out using an activating agent which is regulated by a phosphorous compound such as tributylphosphine, triphenylphosphine, etc.
  • azodicarbonyl compound such as diethyl azodicarboxylate, 1,1′-(diazocarbonyl)dipiperidine, etc., or a reagent such as cyanomethylene tributylphosphorane, or the like, in a solvent such as halogenated hydrocarbons, ethers, aromatic hydrocarbons, etc., under cooling, room temperature or heating.
  • the method can be carried out by using the compound (7) and the compound (8), in which the compound have equal amount or one compound has excessive amount, for example, in the presence of a base such as potassium carbonate, cesium carbonate, sodium methoxide, sodium hydride, etc. in a solvent such as halogenated hydrocarbons, ethers, aromatic hydrocarbons, etc., DMF, and the like, under cooling, room temperature or heating.
  • a base such as potassium carbonate, cesium carbonate, sodium methoxide, sodium hydride, etc.
  • a solvent such as halogenated hydrocarbons, ethers, aromatic hydrocarbons, etc., DMF, and the like
  • the process is a process for obtaining a compound (11) by oxime formation of a compound (10).
  • the method can be carried out using the compound (10) and hydroxylamine or salts thereof, in which they have equal amount or either one of them has excessive amount, in a solvent such as alcohols, acetic acid, pyridine, water, etc. under cooling, room temperature or heating.
  • a solvent such as alcohols, acetic acid, pyridine, water, etc.
  • the process is a process for obtaining a compound (1) by reduction of a compound (11).
  • the reaction can be carried out using the compound (11) and a reducing agent such as a borane-pyridine complex, sodium cyanoborohydride, etc., in which they have equal amount or either one of them has excessive amount, in a solvent such as ethers, alcohols, aromatic hydrocarbons, etc. acetic acid, and the like, under cooling, room temperature or heating.
  • a reducing agent such as a borane-pyridine complex, sodium cyanoborohydride, etc.
  • the compound of the formula (I) is isolated as a substance of a free compound, a pharmaceutically acceptable salt thereof, a hydrate, a solvate or a crystalline polymorph, thereby purifying.
  • the pharmaceutically acceptable salt of the compound of the formula (I) also can be produced by a conventional salt forming reaction.
  • Isolation and purification are carried out by applying normal chemical operations such as extraction, fractional crystallization, fractional chromatography of many types or the like.
  • Various isomers can be produced by selecting a proper raw material, or separated by making use of the difference of physiochemical properties between isomers. For example, an enantiomer can be led to a pure isomer by a general optical resolution (e.g., fractional crystallization leading to diastereomeric salt with an optically-active base or acid, or chromatography using a chiral column, etc., or the like). In addition, the isomer also can be produced from a proper optically-active raw material.
  • a general optical resolution e.g., fractional crystallization leading to diastereomeric salt with an optically-active base or acid, or chromatography using a chiral column, etc., or the like.
  • the isomer also can be produced from a proper optically-active raw material.
  • test examples as described below can be carried out in accordance with known methods. When a commercially available reagent, kit, etc. is used, the test examples can be carried out in accordance with the instruction of the commercial product.
  • the full-length sequence of GPR40 was obtained by a polymerase chain reaction (PCR) to set human genomic DNA (Clontech) as a template.
  • PCR polymerase chain reaction
  • Oligonucleotide which consists of a base sequence represented by SEQ ID NO. 1 was used as a forward primer
  • oligonucleotide which consists of a base sequence represented by SEQ ID NO. 2 was used as a reverse primer.
  • a base sequence including the XbaI recognition site is attached to each 5′ terminus of the forward primer and the reverse primer described above.
  • a cycle consisting of 94° C. (15 sec)/55° C. (30 sec)/72° C. (1 min) was repeated 30 times in the presence of 5% DMSO. As a result, the DNA fragment of about 0.9 kbp was amplified.
  • This DNA fragment was digested with XbaI, followed by inserting into the XbaI site of plasmid pEF-BOS-dhfr (Nucleic Acids Research, 18, 5322, 1990) to obtain plasmid pEF-BOS-dhfr-GPR40.
  • the base sequence of GPR40 gene in plasmid pEF-BOS-dhfr-GPR40 was decided by a dideoxy terminator method using a DNA sequencer (ABI377 DNA Sequencer; Applied Biosystems).
  • the base sequence of GPR40 gene was the same with the base sequence represented by SEQ ID NO. 3.
  • the base sequence represented by SEQ ID NO. 3 had an open reading frame (ORF) of a 903 base, an amino acid sequence predicted from this ORF (300 amino acid) was the same with the amino acid sequence represented by SEQ ID NO. 4
  • a CHO dhfr cell (CHO cell deleting a dihydrofolate reductase (dhfr) gene) was used as a cell in which GPR 40 protein was expressed.
  • the CHO dhfr cells were seeded to become 80 to 90% confluent in an aMEM medium having 10% fetal calf serum (FCS), and cultivated overnight.
  • plasmid pEF-BOS-dhfr-GPR40 per well was transferred generetically thereto using a transfection reagent (Lipofectamine 2000; Invitrogen Corporation). After cultivating for 24 hours subsequent to the gene transfer, the cell were diluted and reseeded. On this occasion, the ⁇ MEM medium having 10% FCS was changed for an ⁇ MEM medium having 10% FCS and no nucleic acid. After 20 days cultivation, formed cell colonies were collected respectively and cultivated, thereby obtaining CHO cells stably expressing GPR40. Among these, cells high-reactive to an oleic acid and a linoleic acid which were intrinsic ligands were selected.
  • the GPR40 agonistic activity was measured with fluctuation of the intracellular calcium concentration as an index by FLIPR (registered trademark, Molecular Devices Corporation).
  • FLIPR registered trademark, Molecular Devices Corporation
  • a CHO cell line expressing human GPR40 was seeded with 6 ⁇ 10 3 per well to a 384-well black plate (Becton, Dickinson and Company), and cultivated in a CO 2 incubator overnight.
  • a luminescent pigment a Calcium-3 assay kit (Molecular Devices Corporation) was used, and dissolved in 10 ml of a HBSS-HEPES buffer (PH7.4, 1 ⁇ HBSS, 20 mM HEPES, Invitrogen Corporation) for a bottle.
  • 35.68 mg of probenecid (Sigma) was dissolved in 250 ⁇ l of 1M NaOH, and then 250 ⁇ l of a HBSS-HEPES buffer was added to blend.
  • Test Method 2 Insulin Secretagogue Action Using MIN6 Cell
  • Insulin secretagogue action of the compound to be inspected was examined using MIN6 cells which were mouse pancreatic ⁇ cell lines. Hereinafter, the test method will be described.
  • MIN6 cells were seeded to set 5 ⁇ 10 4 /well (200 ⁇ l) to a 96-well plate.
  • DMEM 25 mM glucose
  • FBS 10% FBS
  • 2-mercaptoethanol 100 U/ml of penicillin and 100 ⁇ g/ml of streptomycin was used.
  • KRB-HEPES 116 mM NaCl, 4.7 mM KCl, 1.2 mM KH 2 PO 4 , 1.2 mM MgSO 4 , 0.25 mM CaCl 2 , 25 mM NaHCO 3 , 0.005% FFA Free BSA, 24 mM HEPES (pH 7.4)
  • a buffer solution 200 ⁇ l
  • the compound to be inspected having fixed concentration was added to KRB-HEPES having 2.8 mM or 22.4 mM glucose, followed by adding 100 ⁇ l to each well to incubate at 37° C. for 2 hours.
  • the above sample was taken, diluted 100 times, and the concentration of insulin was quantitated by using an insulin MA kit (Amersham RI).
  • the area under the blood concentration-time curve (AUC) of blood glucose levels for 0 to 120 minute(s) was calculated from the blood glucose levels before the blood drawing, and the blood glucose levels at 5, 15, 30, 60, and 120 minutes after the glucose load when 30, 10, 3, 1 or 0.3 mg/kg of the compound to be inspected was orally administered. Then, a dose which showed a significant (Dunnet multiple comparison test) decrease to the control group and a dose in which reduction rate of blood glucose levels after glucose loading was 20% (ED 20 value) were calculated. As a result, the comparative compound (compound of Example 36 described in International Publication No.
  • WO 2005/087710 Pamphlet showed significant decrease in the blood glucose level at a dose of 30 mg/kg, and the ED 20 value thereof was 17.8 mg/kg. Meanwhile, one or more compounds of the invention showed significant decrease in the blood glucose level in spite of a dose of 3 mg/kg or less, and the ED 20 value thereof was 3 mg/kg or less.
  • the compound of the invention has excellent GPR40 receptor agonistic action, therefore, it is obvious that the compound of the invention is useful for insulin secretagogues and an agent for preventing and/or treating diseases associated with GPR40 such as for diabetes mellitus (insulin-dependent diabetes mellitus (type 1 diabetes), non-insulin-dependent diabetes mellitus (type 2 diabetes), borderline thereof (impaired glucose tolerance/ fasting blood glucose)) and the like.
  • a pharmaceutical composition containing one or more kind(s) of the compound of the formula (I) or a pharmaceutically acceptable salt thereof as an active ingredient can be prepared by a usually used method using a usually used excipient for medicine, a carrier for medicine or the like.
  • Administration can be any forms such as oral administration with tablets, pills, capsules, granules, powder medicine, solution or the like; intra-articular, intravenous, intramuscular or the like injectables; or parenteral administration with suppositories, eye-drops, eye ointments, transdermal solutions, ointments, transdermal patches, transmucosal solutions, transmucosal patches, inhalants or the like.
  • a solid composition for oral administration pills, powder medicines, granules or the like was used.
  • one or more kind(s) of active ingredients are mixed with at least one kind of an inert excipient, for example, lactose, mannitol, glucose, hydroxypropylcellulose, microcrystalline cellulose, starch, polyvinylpyrrolidone and/or magnesium metasilicate alminate, etc.
  • the composition may have inert additives, for example, lubricants such as magnesium stearate, disintegrants such as sodium carboxymethyl starch, etc., stabilizers and solubilizing agents by the law of the art.
  • Tablets or pills may be coated with a film which is sugarcoated, soluble in the stomach or enteric, if needed.
  • a liquid composition for oral administration contains a pharmaceutically acceptable opalizer, solution, suspension agent, syrup, elixir or the like, and includes a generally used inert diluents, for example, purified water or ethanol.
  • the liquid composition may contain auxiliary substances such as solubilizing agent, humectants and suspension agent, sweetener, flavor, fragrance and antiseptic agent.
  • the parenteral injectables contain an aseptic aqueous or nonaqueous solution, a suspension agent or an opalizer.
  • aqueous solution for example, distilled water for injection or physiological saline is included.
  • nonaqueous solution for example, there are vegetable oils such as propylene glycol, polyethylene glycol and olive oil; alcohols such as ethanol; polysorbate 80 (official name); and the like.
  • Such composition further may include a tonicity agent, an antiseptic agent, a humectant, an emulsifier, a dispersant, a stabilizer or a solubilizing agent. These are sterilized by filtration through a bacteria filter, blend of antiseptic agents or irradiation. In addition, these produce antiseptic solid composition, and the composition can be used by suspending in antiseptic water or an antiseptic solvent for injection before use.
  • the external preparation includes ointments, plasters, creams, jellies, adhesive skin patches, air sprays, lotions, eye-drops, eye-ointments and the like.
  • ointment bases Generally used ointment bases, lotion bases, aqueous or nonageous solutions, suspension agents, emulsion or the like are included. More specifically, the ointment or the lotion base includes polyethylene glycol, propylene glycol, white petrolatum, bleached wax, polyoxyethylene hydrogenated castor oil, glyceryl monostearate, stearyl alcohol, cetyl alcohol, lauromacrogol, sorbitan sesquioleate and the like.
  • the transmucosal agent such as an inhalant, a transnasal agent, and the like is used in the form of solid, liquid or semi-solid, and can be produced in accordance with conventional known methods.
  • a known excipient further, a pH adjuster, an antiseptic agent, a surfactant, a lubricant, a stabilizer, a thickener, or the like may be optionally added.
  • a device for proper inhalation or insufflations can be used for the administration. For example, using known devices such as a metered-dose inhaler, etc.
  • the compound is administered alone, as a powder of a prescribed mixture, or a solution or suspending solution which is combined with a pharmaceutically carrier.
  • a dry powder inhaler or the like may be for single or multiple administration, and dry powder or a capsule having powder is available.
  • a form of pressured aerosol spray using a preferred gas such as chlorofluoroalkane, hydrofluoroalkane, carbon dioxide, etc. as a proper propellant, or the like can be used.
  • the daily dosage is proper to be approximately 0.0001 to 50 mg/kg per weight, preferably approximately 0.001 to 10 mg/kg, more preferably 0.01 to 1 mg/kg, and administered at one time or in 2 to 4 divided doses.
  • the daily dosage is proper to be approximately 0.0001 to 3 mg/kg per weight, preferably approximately 0.0001 to 0.3 mg/kg, and administered at one time or in multiple divided doses.
  • the dosage is arbitrarily determined depending on an individual case in consideration of symptoms, age, sex and the like.
  • the compound of the formula (I) can be used in combination with various therapeutic agents or agents for preventing a disease expected that the above compound of the formula (I) shows the efficacy.
  • the administration can be concurrent, separate and continuous, or at desired intervals.
  • the concurrently-administered preparation can be combination preparation or formulated separately.
  • the medicine of possible combination can include insulin, GLP-1 receptor agonist, a SU agent, a DPP4 inhibitor, an a glycosidase inhibitor, a SGLT inhibitor, a biguanide agent and an insulin sensitizer.
  • the medicine can include byetta, glibenclamide, glimepiride, sitagliptin, vildagliptin, acarbose, voglibose, metformin, pioglitazone and the like.
  • the production method of the formula (I) will be illustrated in more detail with reference to Examples.
  • the invention is not limited to compounds described in the following Examples.
  • the production methods of the raw material compound are shown in Production Examples.
  • the production method of the formula (I) is not limited to the production method of concrete Examples showing as follows, and the compound of the formula (I) may be produced by the combination of these production methods, or the methods obvious for those skilled in the art.
  • the obtained filtrate was concentrated under reduced pressure, and the obtained residue was purified by silica gel column chromatography (hexane-ethyl acetate) to obtain 54.00 g of methyl 2-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolane-2-yl)benzoate.
  • the solvent was evaporated under reduced pressure, and a saturated aqueous solution of ammonium chloride was added to the residue, and the mixture was extracted with ethyl acetate.
  • the organic layer was washed with a saturated aqueous solution of sodium chloride, and dried over anhydrous magnesium sulfate. After removing the desiccant, the solvent was evaporated under reduced pressure.
  • the obtained residue was purified by silica gel column chromatography (hexane-ethyl acetate) to obtain 8.40 g of methyl 4′- ⁇ [tert-butyl(dimethyl)silyl]oxy ⁇ -2,2′,6′ -trimethylbiphenyl-3-carboxylate.
  • the obtained residue was purified by silica gel column chromatography (hexane-ethyl acetate) to obtain 2.30 g of methyl 4′-hydroxy-2,2′,5′-trimethylbiphenyl-3-carboxylate.
  • lithium aluminum hydride 700 mg was added to THF (40 ml) under ice cooling, and then a solution of methyl 4′- ⁇ [tert-butyl(dimethyl)silyl]oxy ⁇ -2,2′-dimethylbiphenyl-3-carboxylate (4.67 g) in THF (20 ml) was slowly added dropwise. After stirring the reaction mixture under ice cooling for 2 hours, ethyl acetate (0.4 ml) and a saturated aqueous solution of ammonium chloride (10 ml) were slowly added dropwise, followed by stirring at the same temperature for 0.5 hour.
  • the organic layer was sequentially washed with 1 M hydrochloric acid, water and a saturated aqueous solution of sodium chloride, and then dried over anhydrous magnesium sulfate.
  • the desiccant was removed, and then the solvent was evaporated under reduced pressure.
  • the residue was purified by silica gel column chromatography (hexane-ethyl acetate) to obtain 78 mg of (3′-formyl-2′,6-dimethylbiphenyl-3,4-diyl)bis(oxyethane-2,1-diyl)diacetate.
  • the obtained foamy product was dissolved in THF (136 ml), and chlorocarbonylisocyanate (1.53 ml) was added thereto dropwise under ice cooling, followed by stirring at the same temperature for 30 minutes and stirring again at a raised temperature of room temperature for 1 hour.
  • the solvent was evaporated under reduced pressure, and water was added to the obtained residue, followed by extraction with chloroform.
  • the organic layer was washed with a saturated aqueous solution of sodium chloride and dried over anhydrous magnesium sulfate.
  • N,N-dimethylpropane-1,3-diamine (0.18 ml) was added and stirred for 10 minutes, and then 1 M hydrochloric acid was added, followed by extraction with chloroform-2-propanol (10:1).
  • the organic layer was washed with a saturated aqueous solution of sodium chloride and dried over anhydrous magnesium sulfate. After removing the desiccant, the solvent was evaporated under reduced pressure. The obtained residue was purified by silica gel column chromatography (chloroform-methanol) to obtain 424 mg of a foamy product.
  • the obtained foamy product was dissolved in THF (5 ml) and an 1 M aqueous solution of sodium hydroxide (0.79 ml) was added and stirred for 1 hour, and then the solvent was evaporated under reduced pressure.
  • the obtained residue was purified by ODS column chromatography (acetonitrile-water) to obtain a foamy product.
  • diethyl ether was added for powderization, and then collected by filtration to obtain 299 mg of sodium 2-(4- ⁇ [4′-(3-acetamidepropoxy)-2,2′,6′-trimethylbiphenyl-3-yl]methoxy ⁇ benzyl)-3,5-dioxo-1,2,4-oxazolidin-4-ide.
  • the obtained organic layer was washed with a saturated aqueous solution of sodium chloride and dried over anhydrous magnesium sulfate. After removing the desiccant, the solvent was evaporated under reduced pressure, and the obtained residue was purified by silica gel column chromatography (chloroform-methanol) to obtain 278 mg of a foamy product.
  • the obtained foamy product was dissolved in THF (3.75 ml) and an 1 M aqueous solution of sodium hydroxide (0.61 ml) was added, followed by stirring for 1 hour. The solvent was evaporated under reduced pressure, and the obtained residue was purified by ODS column chromatography (acetonitrile-water) to obtain a foamy product.
  • the organic layer was dried over anhydrous magnesium sulfate, and after removing the desiccant, the solvent was evaporated under reduced pressure to obtain a foamy product.
  • acetic acid 5 ml
  • sodium cyanoborohydride 408 mg
  • the reaction mixture was diluted with chloroform, and then an 1 M aqueous solution of sodium hydroxide was added for alkalification, followed by phase separation.
  • the obtained organic layer was dried over anhydrous magnesium sulfate. After removing the desiccant, the solvent was evaporated under reduced pressure.
  • the obtained residue was purified by silica gel column chromatography (chloroform-methanol) to obtain a foamy product.
  • the obtained foamy product was dissolved in THF (15 ml), and under ice cooling, ethoxycarbonylisocyanate (0.23 ml) was added dropwise. After stirring at the same temperature for 1 hour, it was then stirred at room temperature for 1 hour. To the reaction mixture, an 1 M aqueous solution of sodium hydroxide (2.2 ml) was added and stirred at room temperature for 12 hours. To the reaction mixture, a 5% aqueous solution of citric acid was added to adjust the pH to 5, followed by extraction with chloroform. The organic layer was washed with a saturated aqueous solution of sodium chloride, and dried over anhydrous magnesium sulfate.
  • the organic layer was washed with a saturated aqueous solution of sodium chloride, and dried over anhydrous magnesium sulfate. After removing the desiccant, the solvent was evaporated under reduced pressure, and the obtained residue was purified by silica gel column chromatography (chloroform-methanol) to obtain 325 mg of a foamy product.
  • the obtained foamy product was dissolved in THF (7 ml) and an 1 M aqueous solution of sodium hydroxide (0.64 ml) was added, followed by stirring for 1 hour. The solvent was evaporated under reduced pressure, and the obtained residue was purified by ODS column chromatography (acetonitrile-water) to obtain a foamy product.
  • the organic layer was dried over anhydrous magnesium sulfate, and after removing the desiccant, the solvent was evaporated under reduced pressure to obtain the syrup-like substance.
  • a solution of the obtained syrup-like substance in THF (5 ml) was ice-cooled and ethoxycarbonylisocyanate (0.13 ml) was added, followed by stirring for 30 minutes. The temperature of the reaction mixture was raised to room temperature and stirred for 1 hour.
  • an 1 M solution of sodium hydroxide (2.5 ml) was added and stirred at room temperature for 12 hours.
  • 1 M hydrochloric acid was added, followed by extraction with chloroform.
  • the organic layer was dried over anhydrous magnesium sulfate, and after removing the desiccant, the solvent was evaporated under reduced pressure.
  • the obtained residue was purified by silica gel column chromatography (hexane-ethyl acetate) to obtain a syrup-like substance (250 mg).
  • the obtained syrup-like substance (250 mg) was dissolved in THF (5 ml), and an 1 M aqueous solution of sodium hydroxide (0.53 ml) was added, followed by stirring at room temperature for 15 minutes.
  • the obtained residue was purified by silica gel column chromatography (hexane-ethyl acetate) to obtain 700 mg of a foamy product.
  • the obtained foamy product (700 mg) was dissolved in ethanol (3.5 ml) and THF (3.5 ml), and an 1 M aqueous solution of sodium hydroxide (2.7 ml) was added, and then the reaction mixture was stirred at 50° C. for 5 hours.
  • an 1 M aqueous solution of sodium hydroxide 1.3 ml was added and stirred at 50° C. for 1.5 hours.
  • the reaction mixture was cooled to room temperature, and 1 M hydrochloric acid was added for mild acidification, followed by extraction with chloroform.
  • the organic layer was dried over anhydrous magnesium sulfate, and after removing the desiccant, the solvent was evaporated under reduced pressure.
  • the obtained residue was purified by silica gel column chromatography (hexane-ethyl acetate) to obtain 170 mg of gummy substance.
  • the obtained gummy substance (170 mg) was dissolved in THF (5 ml) and an 1 M aqueous solution of sodium hydroxide (0.35 ml) was added, followed by stirring at room temperature for 30 minutes.
  • the obtained residue was purified by silica gel column chromatography (hexane-ethyl acetate) to obtain a foamy product.
  • the obtained foamy product was dissolved in methanol (6 ml), and sodium methoxide (415 mg) was added, followed by stirring at 50° C. for 7 hours.
  • the reaction mixture was cooled down to room temperature, and a 10% aqueous solution of citric acid was added, followed by extraction with chloroform-2-propanol.
  • the organic layer was dried over anhydrous magnesium sulfate, and after removing the desiccant, the solvent was evaporated under reduced pressure.
  • the obtained residue was purified by silica gel column chromatography (hexane-ethyl acetate) to obtain 570 mg of a foamy product.
  • the obtained foamy product (570 mg) was dissolved in THF (10 ml), and an 1 M aqueous solution of sodium hydroxide (1.2 ml) was added, followed by stirring at room temperature for 10 minutes.
  • the organic layer was dried over anhydrous magnesium sulfate, and after removing the desiccant, the solvent was evaporated under reduced pressure.
  • the obtained residue was purified by silica gel column chromatography (hexane-ethyl acetate) to obtain a foamy product.
  • the obtained foamy product was dissolved in THF (10 ml), and 1M hydrochloric acid (10 ml) was added, and then the reaction mixture was stirred at 50° C. for 7 hours.
  • the reaction mixture was cooled to room temperature, and an 1 M aqueous solution of sodium hydroxide and saturated aqueous solution of sodium bicarbonate were added to make the mixture weakly acidic, the mixture was extracted with chloroform.
  • the organic layer was dried over anhydrous magnesium sulfate, and after removing the desiccant, the solvent was evaporated under reduced pressure.
  • the obtained residue was purified by silica gel column chromatography (hexane-ethyl acetate) to obtain 370 mg of a foamy product.
  • the obtained foamy product (370 mg) was dissolved in THF (10 ml), and an 1 M aqueous solution of sodium hydroxide (0.75 ml) was added, followed by stirring at room temperature for 10 minutes.
  • the obtained residue was purified by silica gel column chromatography (chloroform-methanol) to obtain a syrup-like substance (1.43 g), which was dissolved in methanol (4 ml), added with an 1 M aqueous solution of sodium hydroxide (2.83 ml) and purified by ODS column chromatography (acetonitrile-water) to obtain 433 mg of a foamy product.
  • methanol 4 ml
  • ODS column chromatography acetonitrile-water
  • the obtained residue was purified by silica gel column chromatography (chloroform-methanol) to obtain an oily material (400 mg).
  • an oily material 400 mg
  • the organic layer was washed with a saturated aqueous solution of sodium chloride, dried over anhydrous magnesium sulfate, and after removing the desiccant, the solvent was evaporated under reduced pressure, and a syrup-like substance was obtained.
  • the obtained syrup-like substance was dissolved in methanol (3 ml) and THF (3 ml), and sodium cyanoborohydride (149 mg) was added and ice-cooled, and then a 4 M solution of hydrogen chloride in dioxane (1.2 ml) was added dropwise. The temperature of the reaction mixture was raised to room temperature and stirred for 3 hours.
  • the reaction mixture was ice-cooled, and an 1 M aqueous solution of sodium hydroxide was added for mild acidification, and then a saturated aqueous solution of sodium bicarbonate was added for mild alkalification, followed by extraction with chloroform.
  • the organic layer was washed with a saturated aqueous solution of sodium chloride, dried over anhydrous magnesium sulfate, and after removing the desiccant, the solvent was evaporated under reduced pressure, and a syrup-like substance was obtained.
  • a solution of the obtained syrup-like substance in THF (10 ml) was cooled down in an ice-methanol bath, and ethoxycarbonylisocyanate (0.081 ml) was added, followed by stirring for 30 minutes.
  • the organic layer was dried over anhydrous magnesium sulfate, and after removing the desiccant, the solvent was evaporated under reduced pressure.
  • the obtained residue was purified by silica gel column chromatography (hexane-ethyl acetate) to obtain 218 mg of oily material, to which an 1 M aqueous solution of sodium hydroxide (0.425 ml), methanol (3 ml) and THF (3 ml) were added and stirred at room temperature for 5 minutes.
  • a tert-butyl ⁇ 5-[3-( ⁇ 4-[(3,5-dioxo-1,2,4-oxazolidine-2-yl)methyl]phenoxy ⁇ methyl)-2-methylphenyl]-4,6-dimethylpyridin-2-yl ⁇ carbamate hydrochloride (2.19 g) was dissolved in methanol (10 ml), and a 4 M solution of hydrogen chloride in dioxane (4.8 ml) was added, and stirred at room temperature for 13 hours. The solvent was evaporated under reduced pressure, and a saturated aqueous solution of sodium bicarbonate was added to adjust the pH to approximately 8.
  • the organic layer was dried over anhydrous magnesium sulfate, and after removing the desiccant, the solvent was evaporated under reduced pressure.
  • the obtained residue was purified by silica gel column chromatography (chloroform-methanol) to obtain an oily material.
  • the obtained oily material was dissolved in THF (10 ml), added with 5 M hydrochloric acid (2 ml) and stirred at room temperature for 2 hours.
  • a saturated aqueous solution of sodium bicarbonate was added to adjust the pH to approximately 7, followed by extraction with chloroform-2-propanol (10:1), and the obtained organic layer was washed with a saturated aqueous solution of sodium chloride and dried over anhydrous magnesium sulfate.
  • the obtained residue was purified by silica gel column chromatography (chloroform-methanol) to obtain a foamy product.
  • the obtained foamy product was dissolved in methanol (10 ml), cooled down in an ice-methanol bath, added with an 1 M aqueous solution of sodium hydroxide and stirred for 10 minutes, and then the solvent was evaporated under reduced pressure, and purified with ODS column chromatography (acetonitrile-water) to obtain 366 mg of a foamy product.
  • the compound of the formula (I) or a pharmaceutically acceptable salt thereof has GPR40 receptor agonistic action, and can be used as insulin secretagogues and an agent for preventing and/or treating diseases associated with GPR40 such as diabetes mellitus (insulin-dependent diabetes mellitus (type 1 diabetes), non-insulin-dependent diabetes mellitus (type 2 diabetes) and borderline thereof (impaired glucose tolerance/fasting blood glucose)), obesity, and the like.
  • diseases associated with GPR40 such as diabetes mellitus (insulin-dependent diabetes mellitus (type 1 diabetes), non-insulin-dependent diabetes mellitus (type 2 diabetes) and borderline thereof (impaired glucose tolerance/fasting blood glucose)), obesity, and the like.
  • the base sequence represented by SEQ ID NO. 1 of the sequence listing is an artificially-synthesized primer base sequence.
  • the base sequence represented by SEQ ID NO. 2 of the sequence listing is an artificially-synthesized primer base sequence.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
US12/739,501 2007-10-24 2008-10-22 Oxadiazolidinedione compound Abandoned US20100267775A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2007275840 2007-10-24
JP2007-275840 2007-10-24
PCT/JP2008/069164 WO2009054423A1 (ja) 2007-10-24 2008-10-22 オキサジアゾリジンジオン化合物

Publications (1)

Publication Number Publication Date
US20100267775A1 true US20100267775A1 (en) 2010-10-21

Family

ID=40579527

Family Applications (1)

Application Number Title Priority Date Filing Date
US12/739,501 Abandoned US20100267775A1 (en) 2007-10-24 2008-10-22 Oxadiazolidinedione compound

Country Status (16)

Country Link
US (1) US20100267775A1 (es)
EP (1) EP2216330A4 (es)
JP (1) JPWO2009054423A1 (es)
KR (1) KR20100075539A (es)
CN (1) CN101835763A (es)
AR (1) AR069041A1 (es)
AU (1) AU2008314963A1 (es)
CA (1) CA2703793A1 (es)
IL (1) IL205066A0 (es)
MX (1) MX2010004503A (es)
NZ (1) NZ584811A (es)
RU (1) RU2010120681A (es)
SA (1) SA08290669B1 (es)
TW (1) TW200932219A (es)
WO (1) WO2009054423A1 (es)
ZA (1) ZA201002605B (es)

Cited By (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8455500B2 (en) 2009-10-30 2013-06-04 Mochida Pharmaceutical Co., Ltd. 3-hydroxy-5-arylisoxazole derivative
US8476287B2 (en) 2009-12-25 2013-07-02 Mochida Pharmaceutical Co., Ltd. 3-hydroxy-5-arylisothiazole derivative
US8557766B2 (en) 2011-04-27 2013-10-15 Mochida Pharmaceutical Co., Ltd. 3-hydroxyisothiazole 1-oxide derivatives
US9040525B2 (en) 2010-10-08 2015-05-26 Mochida Pharmaceutical Co., Ltd. Cyclic amide derivative
US9072758B2 (en) 2011-04-28 2015-07-07 Mochida Pharmaceutical Co., Ltd. Cyclic amide derivative
US10618916B2 (en) 2018-05-11 2020-04-14 Incyte Corporation Heterocyclic compounds as immunomodulators
US10669271B2 (en) 2018-03-30 2020-06-02 Incyte Corporation Heterocyclic compounds as immunomodulators
US10793565B2 (en) 2016-12-22 2020-10-06 Incyte Corporation Heterocyclic compounds as immunomodulators
US10800768B2 (en) 2016-12-22 2020-10-13 Incyte Corporation Heterocyclic compounds as immunomodulators
US10806785B2 (en) 2016-12-22 2020-10-20 Incyte Corporation Immunomodulator compounds and methods of use
US11401279B2 (en) 2019-09-30 2022-08-02 Incyte Corporation Pyrido[3,2-d]pyrimidine compounds as immunomodulators
US11407749B2 (en) 2015-10-19 2022-08-09 Incyte Corporation Heterocyclic compounds as immunomodulators
US11465981B2 (en) 2016-12-22 2022-10-11 Incyte Corporation Heterocyclic compounds as immunomodulators
US11535615B2 (en) 2015-12-22 2022-12-27 Incyte Corporation Heterocyclic compounds as immunomodulators
US11572366B2 (en) 2015-11-19 2023-02-07 Incyte Corporation Heterocyclic compounds as immunomodulators
US11608337B2 (en) 2016-05-06 2023-03-21 Incyte Corporation Heterocyclic compounds as immunomodulators
US11613536B2 (en) 2016-08-29 2023-03-28 Incyte Corporation Heterocyclic compounds as immunomodulators
US11673883B2 (en) 2016-05-26 2023-06-13 Incyte Corporation Heterocyclic compounds as immunomodulators
US11718605B2 (en) 2016-07-14 2023-08-08 Incyte Corporation Heterocyclic compounds as immunomodulators
US11753406B2 (en) 2019-08-09 2023-09-12 Incyte Corporation Salts of a PD-1/PD-L1 inhibitor
US11760756B2 (en) 2020-11-06 2023-09-19 Incyte Corporation Crystalline form of a PD-1/PD-L1 inhibitor
US11780836B2 (en) 2020-11-06 2023-10-10 Incyte Corporation Process of preparing a PD-1/PD-L1 inhibitor
US11866434B2 (en) 2020-11-06 2024-01-09 Incyte Corporation Process for making a PD-1/PD-L1 inhibitor and salts and crystalline forms thereof
US11866451B2 (en) 2019-11-11 2024-01-09 Incyte Corporation Salts and crystalline forms of a PD-1/PD-L1 inhibitor
US11873309B2 (en) 2016-06-20 2024-01-16 Incyte Corporation Heterocyclic compounds as immunomodulators

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010143733A1 (en) 2009-06-09 2010-12-16 Takeda Pharmaceutical Company Limited Novel fused cyclic compound and use thereof
CN104780915A (zh) 2012-07-11 2015-07-15 埃尔舍利克斯治疗公司 包含他汀、双胍和用于减小心脏代谢风险的其它药剂的组合物
WO2015034820A1 (en) 2013-09-04 2015-03-12 Bristol-Myers Squibb Company Compounds useful as immunomodulators
EA201690888A1 (ru) 2013-11-14 2016-10-31 Кадила Хелзкэр Лимитед Новые гетероциклические соединения
EP3076959B1 (en) 2013-12-04 2018-07-04 Merck Sharp & Dohme Corp. Antidiabetic bicyclic compounds
EP3102198B1 (en) 2014-02-06 2020-08-26 Merck Sharp & Dohme Corp. Antidiabetic compounds
US10144706B2 (en) 2016-09-01 2018-12-04 Bristol-Myers Squibb Company Compounds useful as immunomodulators
CN108003074B (zh) * 2017-12-21 2019-07-05 四川大学华西医院 联苯羧酸类化合物及其制备方法和用途
EP3749305A1 (en) * 2018-02-05 2020-12-16 Université de Strasbourg Compounds and compositions for the treatment of pain
WO2020104578A2 (en) * 2018-11-21 2020-05-28 University Of Copenhagen Modulators of free fatty acid receptor 1 and their use for treatment of diseases
AU2020363377A1 (en) 2019-10-07 2022-04-21 Kallyope, Inc. GPR119 agonists
CA3178994A1 (en) 2020-05-19 2021-11-25 Iyassu Sebhat Ampk activators
AU2021297323A1 (en) 2020-06-26 2023-02-16 Kallyope, Inc. AMPK activators

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5480896A (en) * 1994-01-27 1996-01-02 American Home Products Corporation Aralkyl-1,2,4-oxadiazolidine-3,5-diones as antihyperglycemic agents
US5643931A (en) * 1993-04-30 1997-07-01 Yamanouchi Pharmaceutical Co., Ltd. Bisoxadiazolidine derivative
US5665748A (en) * 1993-02-26 1997-09-09 Takeda Chemical Industries, Ltd. Oxazolidinedione derivatives and their use
US20060258722A1 (en) * 2003-05-30 2006-11-16 Takeda Pharmaceutical Company., Ltd. Condensed ring compound
US20070155808A1 (en) * 2003-12-26 2007-07-05 Tsuneo Yasuma Phenylpropanoic acid derivatives
WO2007123225A1 (ja) * 2006-04-24 2007-11-01 Astellas Pharma Inc オキサジアゾリジンジオン化合物
US20080269220A1 (en) * 2004-03-15 2008-10-30 Tsuneo Yasuma Aminophenylpropanoic Acid Derivative
US20090012093A1 (en) * 2002-11-08 2009-01-08 Kohji Fukatsu Receptor Function Regulator

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH072848A (ja) 1993-04-23 1995-01-06 Sankyo Co Ltd モルホリンおよびチオモルホリン誘導体
JP3762607B2 (ja) 1993-08-09 2006-04-05 武田薬品工業株式会社 ２，４−オキサゾリジンジオン誘導体、その製造法およびそれを含んでなる医薬組成物
US5420146A (en) 1994-05-10 1995-05-30 American Home Products Corporation Di-oxadiazolidine derivatives as antihyperglycemic agents
DK0958296T3 (da) 1996-12-31 2003-08-18 Reddys Lab Ltd Dr Heterocykliske forbindelser, fremgangsmåde til deres fremstilling og farmaceutiske præparater, der indeholder dem, og deres anvendelse i behandlingen af diabetes og beslægtede sygdomme
US7141592B2 (en) 2003-09-25 2006-11-28 Wyeth Substituted oxadiazolidinediones
JP4074616B2 (ja) * 2003-12-25 2008-04-09 武田薬品工業株式会社 ３−（４−ベンジルオキシフェニル）プロパン酸誘導体
US7456218B2 (en) 2003-12-25 2008-11-25 Takeda Pharmaceutical Company Limited 3-(4-benzyloxyphenyl) propanoic acid derivatives

Patent Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5665748A (en) * 1993-02-26 1997-09-09 Takeda Chemical Industries, Ltd. Oxazolidinedione derivatives and their use
US5972970A (en) * 1993-02-26 1999-10-26 Takeda Chemical Industries, Ltd. Oxazolidinedione derivatives, their production and use
US6147099A (en) * 1993-02-26 2000-11-14 Takeda Chemical Industries, Inc. Oxazolidinedione derivatives, their production and use
US5643931A (en) * 1993-04-30 1997-07-01 Yamanouchi Pharmaceutical Co., Ltd. Bisoxadiazolidine derivative
US5480896A (en) * 1994-01-27 1996-01-02 American Home Products Corporation Aralkyl-1,2,4-oxadiazolidine-3,5-diones as antihyperglycemic agents
US20090012093A1 (en) * 2002-11-08 2009-01-08 Kohji Fukatsu Receptor Function Regulator
US20060258722A1 (en) * 2003-05-30 2006-11-16 Takeda Pharmaceutical Company., Ltd. Condensed ring compound
US20070155808A1 (en) * 2003-12-26 2007-07-05 Tsuneo Yasuma Phenylpropanoic acid derivatives
US20080269220A1 (en) * 2004-03-15 2008-10-30 Tsuneo Yasuma Aminophenylpropanoic Acid Derivative
WO2007123225A1 (ja) * 2006-04-24 2007-11-01 Astellas Pharma Inc オキサジアゾリジンジオン化合物
US20090186909A1 (en) * 2006-04-24 2009-07-23 Kenji Negoro Oxadiazolidinedione Compound

Cited By (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8455500B2 (en) 2009-10-30 2013-06-04 Mochida Pharmaceutical Co., Ltd. 3-hydroxy-5-arylisoxazole derivative
US8476287B2 (en) 2009-12-25 2013-07-02 Mochida Pharmaceutical Co., Ltd. 3-hydroxy-5-arylisothiazole derivative
US9040525B2 (en) 2010-10-08 2015-05-26 Mochida Pharmaceutical Co., Ltd. Cyclic amide derivative
US8557766B2 (en) 2011-04-27 2013-10-15 Mochida Pharmaceutical Co., Ltd. 3-hydroxyisothiazole 1-oxide derivatives
US8629102B2 (en) 2011-04-27 2014-01-14 Mochida Pharmaceutical Co., Ltd. 3-hydroxyisothiazole 1-oxide derivatives
US8765752B2 (en) 2011-04-27 2014-07-01 Mochida Pharmaceutical Co., Ltd. 3-hydroxyisothiazole 1-oxide derivatives
US9072758B2 (en) 2011-04-28 2015-07-07 Mochida Pharmaceutical Co., Ltd. Cyclic amide derivative
US11407749B2 (en) 2015-10-19 2022-08-09 Incyte Corporation Heterocyclic compounds as immunomodulators
US11572366B2 (en) 2015-11-19 2023-02-07 Incyte Corporation Heterocyclic compounds as immunomodulators
US11866435B2 (en) 2015-12-22 2024-01-09 Incyte Corporation Heterocyclic compounds as immunomodulators
US11535615B2 (en) 2015-12-22 2022-12-27 Incyte Corporation Heterocyclic compounds as immunomodulators
US11608337B2 (en) 2016-05-06 2023-03-21 Incyte Corporation Heterocyclic compounds as immunomodulators
US11673883B2 (en) 2016-05-26 2023-06-13 Incyte Corporation Heterocyclic compounds as immunomodulators
US11873309B2 (en) 2016-06-20 2024-01-16 Incyte Corporation Heterocyclic compounds as immunomodulators
US11718605B2 (en) 2016-07-14 2023-08-08 Incyte Corporation Heterocyclic compounds as immunomodulators
US11613536B2 (en) 2016-08-29 2023-03-28 Incyte Corporation Heterocyclic compounds as immunomodulators
US11465981B2 (en) 2016-12-22 2022-10-11 Incyte Corporation Heterocyclic compounds as immunomodulators
US11787793B2 (en) 2016-12-22 2023-10-17 Incyte Corporation Heterocyclic compounds as immunomodulators
US11339149B2 (en) 2016-12-22 2022-05-24 Incyte Corporation Heterocyclic compounds as immunomodulators
US10806785B2 (en) 2016-12-22 2020-10-20 Incyte Corporation Immunomodulator compounds and methods of use
US11566026B2 (en) 2016-12-22 2023-01-31 Incyte Corporation Heterocyclic compounds as immunomodulators
US10800768B2 (en) 2016-12-22 2020-10-13 Incyte Corporation Heterocyclic compounds as immunomodulators
US10793565B2 (en) 2016-12-22 2020-10-06 Incyte Corporation Heterocyclic compounds as immunomodulators
US10669271B2 (en) 2018-03-30 2020-06-02 Incyte Corporation Heterocyclic compounds as immunomodulators
US11124511B2 (en) 2018-03-30 2021-09-21 Incyte Corporation Heterocyclic compounds as immunomodulators
US10906920B2 (en) 2018-05-11 2021-02-02 Incyte Corporation Heterocyclic compounds as immunomodulators
US11414433B2 (en) 2018-05-11 2022-08-16 Incyte Corporation Heterocyclic compounds as immunomodulators
US10618916B2 (en) 2018-05-11 2020-04-14 Incyte Corporation Heterocyclic compounds as immunomodulators
US11753406B2 (en) 2019-08-09 2023-09-12 Incyte Corporation Salts of a PD-1/PD-L1 inhibitor
US11401279B2 (en) 2019-09-30 2022-08-02 Incyte Corporation Pyrido[3,2-d]pyrimidine compounds as immunomodulators
US11866451B2 (en) 2019-11-11 2024-01-09 Incyte Corporation Salts and crystalline forms of a PD-1/PD-L1 inhibitor
US11760756B2 (en) 2020-11-06 2023-09-19 Incyte Corporation Crystalline form of a PD-1/PD-L1 inhibitor
US11780836B2 (en) 2020-11-06 2023-10-10 Incyte Corporation Process of preparing a PD-1/PD-L1 inhibitor
US11866434B2 (en) 2020-11-06 2024-01-09 Incyte Corporation Process for making a PD-1/PD-L1 inhibitor and salts and crystalline forms thereof
US12084443B2 (en) 2020-11-06 2024-09-10 Incyte Corporation Process of preparing a PD-1/PD-L1 inhibitor

Also Published As

Publication number Publication date
CA2703793A1 (en) 2009-04-30
JPWO2009054423A1 (ja) 2011-03-03
CN101835763A (zh) 2010-09-15
EP2216330A4 (en) 2011-09-14
AR069041A1 (es) 2009-12-23
AU2008314963A1 (en) 2009-04-30
IL205066A0 (en) 2010-11-30
MX2010004503A (es) 2010-07-06
ZA201002605B (en) 2011-06-29
NZ584811A (en) 2011-06-30
TW200932219A (en) 2009-08-01
EP2216330A1 (en) 2010-08-11
SA08290669B1 (ar) 2011-07-20
RU2010120681A (ru) 2011-11-27
WO2009054423A1 (ja) 2009-04-30
KR20100075539A (ko) 2010-07-02

Similar Documents

Publication Publication Date Title
US20100267775A1 (en) Oxadiazolidinedione compound
US7968552B2 (en) Oxadiazolidinedione compound
US10766890B2 (en) Hepatitis B core protein modulators
US9278968B2 (en) Imidazopyridine compounds
ES2383239T3 (es) Compuestos de ácidos policíclicos útiles como antagonistas de CRTH2 y como agentes antialérgicos
US9062032B2 (en) Aminoalkyl-substituted N-thienylbenzamide derivative
US8367702B2 (en) Quinolone derivative
US20120035196A1 (en) Carboxylic acid compound
US8153658B2 (en) Piperidine derivative or salt thereof
JP2011016722A (ja) チアゾリジンジオン化合物
US20100152165A1 (en) Carboxylic acid derivatives
US20090062366A1 (en) Pyrrolidine derivative or salt thereof
US11814375B2 (en) Heterocyclic compounds
US20100204472A1 (en) Indane acetic acid derivatives and their use as pharmaceutical agents, intermediates, and method of preparation
WO2010123017A1 (ja) テトラゾール化合物
US20140094456A1 (en) Anti-fibrotic pyridinones
US20140200215A1 (en) Lysophosphatidic acid receptor antagonists
US20200392150A1 (en) Diaryl-B-Lactam Compound and Preparation Method and Pharmaceutical Use Thereof
US20210238192A1 (en) Vascular adhesion protein-1 (vap-1) modulators and therapeutic uses thereof
US20100125059A1 (en) 1-biarylazetidinone derivative
US20220251039A1 (en) Diaryl-B-Lactam Compound and Preparation Method and Pharmaceutical Use Thereof
US20120277208A1 (en) Benzamide compound
US9399038B2 (en) Benzothiophene compound
US20170290824A1 (en) 2-aminothiazole derivative or salt thereof

Legal Events

Date Code Title Description
AS Assignment

Owner name: ASTELLAS PHARMA INC., JAPAN

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:NEGORO, KENJI;IWASAKI, FUMIYOSHI;OHNUKI, KEI;AND OTHERS;REEL/FRAME:024282/0140

Effective date: 20100302

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION